$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Analysis of the effectiveness and adverse reactions of Zangda in the treatment of non-small cell lung cancer
2025-10-19 11:44:20
Check Details
How many days will it take for the side effects of paclitaxel injection chemotherapy to get better?
2025-10-19 11:44:20
Check Details
Can injectable paclitaxel be used to treat advanced lung cancer?
2025-10-19 11:44:20
Check Details
The efficacy of the second-generation ALK inhibitor Zangda in non-small cell lung cancer
2025-10-19 11:44:20
Check Details
The second generation targeted therapy drug for lung cancer-Dacomitinib
2025-10-19 11:44:20
Check Details
Does paclitaxel for injection need to be stored away from light?
2025-10-19 11:44:20
Check Details
Safety and effectiveness of Zangda in the treatment of ALK-positive metastatic non-small cell lung cancer
2025-10-19 11:44:20
Check Details
How should patients with lung cancer use Zangada correctly?
2025-10-19 11:44:20
Check Details
Analysis of the efficacy and adverse reactions of XL184 in the treatment of non-small cell lung cancer
2025-10-19 11:44:20
Check Details
None
2025-10-19 11:44:20
Check Details
Gitarel can treat non-small cell lung cancer with EGFR gene mutations and lung squamous cell carcinoma with disease progression after chemotherapy
2025-10-19 11:44:20
Check Details
Gitari has good efficacy in treating lung squamous cell carcinoma
2025-10-19 11:44:20
Check Details
1
2
...
3879
3880
3881
3882
3883
3884
3885
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
2
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)
3
Chemical Structure of Capivasertib: A Novel AKT Inhibitor
4
Capivasertib: An AKT Inhibitor for Breast and Prostate Cancer
5
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
6
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
7
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
8
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
9
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
10
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
11
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
12
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice